Physician profile
Amanda Boulos
NPI 1194503722
$1,822.63
in general payments reported to CMS, 2019-2025
12 companies · $1,823 in 2025
The $1,823 reported for 2025 was more than what 95% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,041 · Food and Beverage: $746 · Education: $36.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,040.58 |
| Food and Beverage | $746.05 |
| Education | $36.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,332.30 | 2025 | Interstim |
| Karl Storz Endoscopy-America | $122.37 | 2025 | |
| Procept Biorobotics Corporation | $71.18 | 2025 | |
| Endo USA, INC. | $71.02 | 2025 | Xiaflex, Aveed |
| Teleflex LLC | $42.53 | 2025 | Urolift, Barrigel |
| Antares Pharma, INC. | $38.60 | 2025 | Xyosted |
| Verity Pharmaceuticals INC. | $38.19 | 2025 | Tlando, Trelstar |
| Merck Sharp & Dohme LLC | $26.30 | 2025 | Keytruda, Keytruda Qlex |
| Abbvie INC. | $22.33 | 2025 | |
| C. R. Bard, INC. & Subsidiaries | $22.09 | 2025 | Magic3 Go Intermittent Urinary Catheter |
| Sumitomo Pharma America, INC. | $18.58 | 2025 | Gemtesa |
| Boston Scientific Corporation | $17.14 | 2025 | Bulkamid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Boulos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.